PromarkerD outperforms standard of care tests for DKD
Filed with ASX · · 11 pages · English
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Proteomics awarded $100,000 manufacturing funding
- September 2021 Quarterly Activities Report and Appendix 4C
- Clinical utility study shows benefit of PromarkerD testing
- Proteomics contracts Biotem to manufacture PromarkerD kits
- Proteomics to collaborate to validate test for endometriosis
Later from Proteomics International Laboratories
- PromarkerD distribution network expands to Britain
- Proteomics receives $1.2 million in R&D tax incentive
- Proteomics secures major pharmacokinetic testing contract
- December 2021 Quarterly Activities Report and Appendix 4C
- Unique panel of biomarkers identified for oesophageal cancer
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories